Akums Drugs & Pharmaceuticals Ltd, a leading name in the pharmaceutical industry, is creating waves with its initial public offering (IPO) to be launched from July 30, 2024, to August 1, 2024.
The event marks a significant milestone for the company, providing investors with a unique opportunity to be a part of its growth journey.
Company Background
Established with a vision to deliver superior pharmaceutical solutions, Akums Drugs & Pharmaceuticals Ltd has established itself as a leading Contract Development and Manufacturing Organization (CDMO).
The company boasts a wide range of pharmaceutical products catering to both domestic and international markets.
IPO Details
The IPO of Akums Drugs & Pharmaceuticals Ltd is scheduled to open on July 30, 2024, and close on August 1, 2024. Here are the important details:
- Open Issue: July 30, 2024
- Issue closes: 1 August 2024
- Lot Size: 22 Equity Shares
- Minimum amount: Rs 14,938
- Price Band: Rs. 646 Rs. 679
- Issue Size: Rs. 1856.74 crores
- Listing: NSE & BSE
Product Portfolio
Akums offers a wide range of products, including:
- Tablets and Capsules: Key products in various therapeutic segments.
- Liquid Orals and Vials: Covering a wide range of liquid formulations.
- Ampoules and blow field seals: for sterile injection solutions.
- Topical preparations and eye drops: meeting dermatological and ophthalmic needs.
- Dry Powder Injections and Gummies: Innovative Dosage Forms for Targeted Delivery.
Strength Of The Company
- Largest CDMO: Akums is India’s largest CDMO, serving a large client base with a reputation for quality and reliability.
- Diverse Client Base: The company has established long-term relationships with numerous clients ensuring steady business.
- Growing R&D Capability: With significant investment in research and development, Akums continues to innovate across its product portfolio.
Risk Factors
Investors should consider the following risks:
- Dependence on third-party suppliers: Dependence on suppliers for raw materials can affect operations if delays or disruptions occur.
- Past non-compliance issues: The company had previously issued equity shares to more than 49 investors, which may not have been in compliance with the Companies Act, 1956.
- Financial losses: Akums have suffered losses in the past and may face similar challenges in the future.
Financial Performance
Recent financial highlights of Akums Drugs & Pharmaceuticals Ltd point to its strong growth trajectory. The company has seen consistent revenue growth supported by strong profit margins. This economic stability is a positive indicator for potential investors.
Market Conditions
Akums has a strong position in the pharmaceutical industry, competing with other major players. Its significant market share and influence is a testament to its quality products and reliable services.
Future prospects
The future looks promising for Akum with plans to expand and enter new markets. The company’s continued innovation and growth strategies are likely to lead to further success.
Investor considerations
Why Investors Should Consider Akums Drugs & Pharmaceuticals Ltd?
Strong market position: Leading CDMO with a diverse product portfolio.
Growth Prospects: Continuous research and development and expansion plans.
Financial Stability: Positive revenue growth and profit margins.
How to Apply for IPO
Participating in an IPO is straightforward. Here are the steps:
- Open a demat account: Make sure you have an active demat account.
- Link your bank account: Link your bank account with your demat account for seamless transactions.
- Visit the IPO Portal: Access the IPO application through your broker or online trading platform.
- Fill Details: Provide required details and submit your application.
- Monitor Allotment: Monitor the allotment status and finalize your investment.
Expert opinion
Analysts have a positive outlook on the Akums IPO, highlighting the market’s strong position and growth potential. Market expectations are high and experts believe that this IPO could be a lucrative opportunity for investors.
In summary, Akums Drugs & Pharmaceuticals Ltd’s IPO presents an exciting investment opportunity. With its broad product portfolio, strong market presence, and continued growth, Akums is well-positioned for future success. However, potential investors should consider the associated risks before making a decision.
Read More: Understanding the Role of Liquidity in Trading
Frequently Asked Questions
1. What is the IPO date for Akums Drugs & Pharmaceuticals Ltd?
The IPO opens on July 30, 2024, and closes on August 1, 2024.
2. What is the lot size for IPO?
Lot size is 22 equity shares.
3. What is the price band for an IPO?
Price Band Rs. 646 Rs. 679.
4. Where will the IPO be listed?
The IPO will be listed on NSE and BSE.
5. What are the risks associated with investing in this IPO?
Risks include reliance on third-party suppliers, past non-compliance issues, and a history of financial losses.